PARIMATCH
26.6.2020 09:02:04 CEST | Business Wire | Press release
Sergey Portnov, CEO of Parimatch, took to the virtual stage yesterday at Collision at Home – a global virtual conference which brings together tech leaders and high-potential start-ups to discuss the issues affecting the tech industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005045/en/
During his speech, Sergey Portnov captivated Collison at Home’s 30,000 strong audience with his experience of transforming Parimatch from a physical bookmaker into a leading international tech and entertainment brand, giving viewers his top five tips on tech transformation.
On transforming into a tech business, Sergey Portnov said:
“At Parimatch we are obsessed with technology. We are a business built by businesspeople with management backgrounds, but now we have taken a major step to becoming a tech business – an endless journey with no destination.
“Tech can either be used as a tool, or can be used to describe a culture, a mindset. Previously at Parimatch, we used tech as a tool, but not anymore. Tech isn’t something which can be outsourced, it has to flow through your DNA. Only once you have this tech culture ingrained in your business will your company start to move ahead.”
Sergey’s top five tips on tech transformation:
Lesson 1 – Accept the sacrifice
“In the journey to tech transformation, you need to accept that you will lose things along the way. You may lose employees, customers, partners, maybe even revenue. Whilst this can be painful, this loss has to be accepted in order to transform and ultimately become stronger.”
Lesson 2 – Hire the best
“Don’t take the easy approach when it comes to hiring talent. We all know that it is people who make (or break) a business. Invest in the best people, and pay them a lot. People should be a serious financial investment. But don’t just pay them well, give them freedom in their role. Motivate them, and give them time to shine.”
Lesson 3 – Speed is of the essence
“For me, tech means speed. Every aspect of a tech business needs to be working at speed. The sports and betting industry are very fast paced, so we are able to surround our brand with that speedy energy. Be audacious and brave, create a culture of speed.”
Lesson 4 – Build company culture
“We are continually working on how to foster loyalty from our existing employees. We work with all of our people and spend time building culture and values. These aren’t just words on paper, we live them and people can see them in our actions. Values need to be authentic, and are essential to building a positive culture, and need to form the backbone of a business.”
Lesson 5 – Balance experience with ambition
“It is important to balance experience with ambition. When one outweighs the other, it causes problems. We were ambitious with little experience once upon a time, we made mistakes and learnt from them. On the other hand, you have businesses with lots of experience but no ambition, they have become complacent and are not likely to last into the future. The ideal balance is 51% ambition and 49% experience.”
A recording of Sergey Portnov’s speech can be viewed here: https://www.youtube.com/watch?v=CQ98g1U-doU&feature=youtu.be
-ENDS-
ABOUT PARIMATCH
Parimatch brings together technology, business and sport to deliver seamless entertainment powered by innovation. Founded in 1994, Parimatch has grown to become one of the largest betting companies in Europe and the CIS, and continues to explore new markets to enter. The business operates with a digital first mindset, and is constantly developing and improving the quality of its customer experience, which is enjoyed in 60 countries across the world. Parimatch’s winning team of brand ambassadors include Conor McGregor, Mike Tyson, Petr Yan and the Shevchenko sisters. Parimatch is also the title sponsor of the popular esports team Virtus.pro, and is the exclusive betting partner to UFC in the CIS region.
ABOUT COLLISION
Collision is “America’s fastest growing tech conference” created by the team behind Web Summit. In five years, Collision has grown from 2,500 to an expected 25,000 attendees from more than 120 countries. Attendees include CEOs of both the world’s fastest growing startups and the world’s largest companies, alongside leading investors and media.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200626005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom